neolife vs Cerbo: Where the Chart Ends and the Order Rail Begins

Is neolife or Cerbo the better fit for a telehealth operator? Mostly they are not alternatives. Cerbo is a chart-centric EHR built for functional medicine, direct primary care, and cash-based practices. neolife is the order rail that carries a storefront checkout into a compounding pharmacy and back. A direct-to-consumer Rx operator usually needs both, because neither covers the other's layer.

That disappoints anyone who came looking for a winner, but it is the more useful answer. The question worth asking is not which product wins a feature grid. It is where your operation breaks when a chart-centric EHR sits behind a direct-to-consumer storefront, and what has to exist in the middle so nobody is retyping orders between three systems.

What is Cerbo actually built for?

Cerbo is built for practice-based clinical work. Per its public materials, it serves functional and integrative medicine, direct primary care, cash-based practices, IV and BHRT clinics, and medical spas and aesthetics. The center of gravity is the chart: notes, labs, prescriptions, supplements, scheduling, and the patient portal that hangs off them. It is a clinical system, and it says so.

The published feature set backs that up. According to Cerbo's own features documentation (cer.bo), the product includes:

• Charting with reusable "Chart Parts" templating for notes, diagnoses, prescriptions, and lab orders
• Integrations with more than 40 standard and functional laboratories, with abnormal, high, low, and critical results flagged on incoming electronic results
• eRx to the pharmacy "including compounded and controlled substances eRx" or efax, with the nationwide pharmacy database included as standard
• A patient portal where patients can view and edit preferred pharmacies and request refills
• Supplement and inventory management, including import from online dispensaries such as Fullscript
• A documented REST API with configurable webhooks, published at docs.cer.bo

Read the third bullet twice, because it settles a claim you will hear from vendors on our side of the fence. Cerbo can already send a compounded prescription. Anyone telling you that a chart-centric EHR cannot reach a compounding pharmacy is selling you something. The prescription is not the seam. The seam is everything wrapped around that prescription once the order originates at a storefront checkout instead of in an exam room.

Where Cerbo is clearly the right buy

If your business is a practice, buy practice software. A DPC clinic running a membership panel, an integrative medicine practice ordering dozens of lab panels a week, a BHRT clinic writing compounded scripts patient by patient in a visit: those are the workloads Cerbo was designed around, and no fulfillment rail substitutes for a chart. Cerbo also publishes its pricing openly, which is rarer than it should be in health IT. Its July 2026 pricing page lists $281 per month for a full-time prescribing provider, $256 non-prescribing, $127 supporting, and $63 for additional staff, against a one-time $1,195 setup fee, with the patient portal at $79 per month and telemedicine at $27 to $39. It states no long-term contracts and no cancellation fees. For a clinic, that is a legible buy.

Where does a direct-to-consumer Rx operator hit the seam?

At the point where commerce meets fulfillment. A chart-centric EHR assumes the encounter comes first and the order follows from it. A direct-to-consumer Rx business runs the opposite way: the order arrives first, at checkout, and a clinical decision has to be attached to it before anything can be dispensed. Chart-shaped systems are not designed to run in that direction, and that mismatch is structural rather than a missing feature.

Play it out concretely. A patient buys a non-controlled 503A compounded therapy on your storefront at 11pm. Between that click and a package leaving the pharmacy, six things have to happen, in order, without a human retyping anything:

1. Intake has to be captured and bound to that specific order, not to a generic contact form.
2. Eligibility and compliance rules have to run before a provider ever sees it.
3. A licensed provider has to review and approve, or decline, with the decision recorded.
4. An approved order has to be dispatched to the right compounding pharmacy in that pharmacy's format.
5. Fill and shipment status has to come back and land on the commerce order the customer can actually see.
6. The refill has to fire on schedule, re-run the same gates, and dispatch again.

Steps one through three touch a chart. Steps four through six are commerce and logistics. A chart-centric EHR is authoritative for the clinical record and, in Cerbo's case, can transmit the script. What it is not built to be is the thing that holds the order as an object across all six steps. That is the seam, and we walk through its mechanics in how a compounding pharmacy API integration carries a telehealth order.

The Shopify integration is real, and it is not this

Cerbo does integrate with Shopify, and it is worth being precise about what that integration is, because the name invites the wrong assumption. Per Cerbo's help documentation, the Shopify integration links a Shopify webstore to EHR inventory so that in-stock numbers stay synced between the online store and in-office inventory when items are dispensed through a patient's chart or sold through the store. That is genuinely useful, and for a practice selling supplements and retail products it removes real manual work.

It is an inventory sync. It moves stock counts. It does not carry a patient's compounded order through intake, provider approval, pharmacy dispatch, and status return. Cerbo's public integration directory lists 67 integrations, of which 42 are laboratories, and does not name a compounding pharmacy among them. That is not a knock on Cerbo, whose positioning claims nothing of the sort. It is the boundary of the layer. The commerce-side version of the problem is our piece on Shopify compounding pharmacy integration.

The re-keying tax

When the seam is unstaffed, people fill it: someone opens the storefront admin to read the order, opens the chart to find the patient and attach intake, chases the provider for approval, opens the pharmacy's own portal to confirm the fill, then returns to the storefront to update the customer. Every hop is a transcription opportunity and a place an order stalls silently overnight. We named the pattern in the five-portal problem, and it is a reliable predictor of an operations team that cannot scale past a few hundred orders a month.

Who is responsible for which layer?

Split by responsibility rather than by feature and the picture stops being a contest. Cerbo owns the clinical rows, neolife owns the order rows, and the ones in the middle are where a direct-to-consumer operator gets hurt.

Layer	Chart-centric EHR (Cerbo)	Order rail (neolife)	Where the gap shows up
Clinical chart and record	Owns it: notes, labs, history, portal	Not its job	None; this is settled
Patient intake	Clinical intake tied to an encounter	Order-bound intake tied to a checkout	Intake exists twice and is bound to the wrong object
Provider approval	eRx and clinical sign-off in the chart	Hard gate before any dispatch	Approval is not attached to the commerce order
Storefront and checkout	Not its job	Sits on top of yours	Checkout has no downstream state
Compounding pharmacy dispatch	eRx or efax to a pharmacy	Cross-pharmacy routing in each pharmacy's format	Manual portal work, per pharmacy
Refills and subscriptions	Portal refill requests	Scheduled re-run of intake, gates, and dispatch	Refills drift out of sync with billing
System of record	Clinical record	Order and patient relationship	Split ownership if nobody designs it

The row that decides it

Read the last row slowly. Every other row is a workflow question you can solve with effort. System of record is a leverage question, and it determines what you can renegotiate later. neolife is built so the operator stays system of record for the patient relationship and the order history, the asset that makes changing pharmacies a routing change instead of a migration. A clinical record you control in an EHR you can export from is compatible with that; a bundled platform that owns your patient database is not. The full argument is in telehealth patient data ownership and the system of record.

Does neolife replace Cerbo, or Cerbo replace neolife?

Neither, and that is the point of the piece. neolife is the fulfillment rail for telehealth: AI-native intake, compliance, and cross-pharmacy order routing that sits on top of the compounding pharmacy a clinic already uses. It does not want your chart, your care plans, your lab interfaces, or your scheduling. Those are Cerbo's job and Cerbo is good at them.

What neolife deliberately does not do is worth stating plainly, because restraint is the product:

• It does not replace your EHR, and it does not ask you to migrate a chart.
• It does not replace the pharmacy's fill backbone. On systems like LifeFile the correct move is to overlay the thin intake and routing layer and leave the sticky dispensing backbone alone.
• It does not take over your storefront. You keep your commerce layer, your brand, and your customer.
• It does not dispense anything without a licensed provider approving the order first.

That last constraint is not marketing. Compounded drugs are not FDA-approved, and as the FDA states, "FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) is built around a valid prescription for an identified individual patient. When there is no premarket review standing behind the product, the prescriber's judgment and a documented, auditable order trail are what the safety case actually rests on. A rail that lets an order skip the provider gate is not a faster rail, it is a liability. The broader clinic-side versus pharmacy-side distinction is laid out in clinic-side rail versus pharmacy-side software.

What does running both actually cost?

Cerbo is priced per seat and publishes the numbers, so you can model it before a sales call. That scales with headcount, which is the right shape for a clinical system, because clinical work is done by people.

neolife is priced differently on purpose: a flat fair-market-value SaaS fee with a per-order buy-down, and pharmacies pay nothing to be on the rail. That structure is chosen for a legal reason as much as a commercial one. Percentage-of-value pricing, spreads, and pharmacy take-rates put you in the neighborhood of federal fee-splitting and kickback concerns, and they point the vendor's incentives at maximizing a cut rather than getting orders filled correctly. A flat fee plus volume buy-down means the marginal cost per order falls as you grow, instead of the vendor's share rising.

The combined number is not the interesting comparison anyway. Compare either against the loaded cost of the coordinator whose job is currently retyping orders between three screens, and against the orders that quietly die in that gap every week.

So do you need both, or one?

Work it in this order and it usually resolves in two questions.

1. Is your revenue driven by visits or by a storefront? Visits mean you need the chart first. Storefront means you need the rail, and probably a chart underneath it.
2. Do you have a clinical record already? If not, buy the EHR first. An order rail with nothing clinical behind it is not a business.
3. Are orders moving from checkout to pharmacy without a human retyping them? If a person is the integration, you have found the seam.
4. Could you add a second compounding pharmacy next quarter without rebuilding anything? If the answer is no, that is the lock-in you are currently paying for, whether or not it shows on an invoice.

Most operators asking this question already run Cerbo or something like it and have discovered that the chart is the part that works. The move that follows is the same one every time: keep the clinical system, add a rail underneath the commerce layer, and stop asking people to be middleware.

The short version

Cerbo is a capable chart-centric EHR for practice-based medicine, with real lab depth, compounded eRx, open pricing, and an API. neolife is the order rail from checkout to compounding pharmacy, with provider approval as a hard gate and the operator as system of record. They meet at intake and otherwise stay in separate lanes. Anyone framing this as a head-to-head is either confused about the layers or hoping you are.

If your chart is handled and the storefront-to-pharmacy handoff is the part that hurts, that is precisely the overlay we build: it sits on top of the pharmacy you already use, keeps a licensed provider on every order, and leaves your storefront and your data where they are. Talk to us and we will map your current stack layer by layer before anyone touches anything.

This article is for informational purposes only and is not legal, medical, or regulatory advice; consult qualified counsel and licensed clinicians for your specific situation.